Ask AI
ProCE Banner Activity

ClinicalThought Forum: Improving Knowledge of Multiple Myeloma Guidelines and Evidence-Based Clinical Practice

Clinical Thought

Experts who serve on the National Comprehensive Cancer Network MM guideline panel answer your questions related to the program titled, “Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice.” This social media forum provides you with ongoing access to experts for your questions and challenging cases throughout the certified life of this program.

Released: August 31, 2026

Review Activity

Share

Provided by

Provided by National Comprehensive Cancer Network in collaboration with Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by educational grants from AstraZeneca, Johnson & Johnson, and Sanofi.

AstraZeneca

Johnson & Johnson

Sanofi

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Target Audience

This educational activity is intended for hematologists, oncologists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals who care for individuals with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Initiate timely systemic treatment for appropriate patients based on risk assessment and the latest multiple myeloma diagnostic and staging criteria

  • Develop individualized treatment strategies for patients with newly diagnosed multiple myeloma through consideration of the available clinical data as well as NCCN Guidelines, risk assessment, comorbidities, and patient age/fitness and preferences

  • Select optimal sequencing and bridging therapies for patients with relapsed/refractory multiple myeloma based on individual patient and disease characteristics, as well as NCCN Guidelines recommendations and response to and tolerance of previous therapies

  • Appraise the latest clinical data for current and emerging therapies/regimens for patients with multiple myeloma

  • Implement strategies to improve access, quality of care, and equitable clinical trial enrollment for all patients with multiple myeloma

Financial Disclosures

Primary Author

Larry D. Anderson, Jr., MD, PhD, FACP: consultant/advisor/speaker: AbbVie, Alexion, Amgen, Arcellx/Kite, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Cellectar, GSK, Janssen, Johnson & Johnson, Karyopharm, Legend Biotech, Pfizer, Prothena, Sanofi.

Rachid C. Baz, MD: researcher: AbbVie, Bristol Myers Squibb, CellCentric, Janssen, Regeneron; consultant/advisor/speaker: Bristol Myers Squibb, Janssen, Sanofi.

Carol Ann Huff, MD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Janssen, Legend, Prothena; researcher: Janssen, Prothena.